These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37060435)

  • 1. Therapeutic strategy aiming at R0 resection for borderline-resectable esophageal squamous cell carcinoma using induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil.
    Nakajima M; Muroi H; Kikuchi M; Kubo T; Inoue N; Ihara K; Nakagawa M; Morita S; Nakamura T; Kojima K
    Gen Thorac Cardiovasc Surg; 2023 Oct; 71(10):584-590. PubMed ID: 37060435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Benefits of Docetaxel Plus Cisplatin and 5-Fluorouracil Induction Therapy in Conversion to Curative Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma.
    Takeuchi M; Kawakubo H; Mayanagi S; Yoshida K; Irino T; Fukuda K; Nakamura R; Wada N; Takeuchi H; Kitagawa Y
    World J Surg; 2019 Aug; 43(8):2006-2015. PubMed ID: 30972432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction chemoradiotherapy including docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal cancer.
    Hashimoto M; Shirakawa Y; Maeda N; Tanabe S; Noma K; Sakurama K; Katsui K; Nishizaki M; Fujiwara T
    Esophagus; 2020 Apr; 17(2):127-134. PubMed ID: 31897761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter Randomized Phase 2 Trial Comparing Chemoradiotherapy and Docetaxel Plus 5-Fluorouracil and Cisplatin Chemotherapy as Initial Induction Therapy for Subsequent Conversion Surgery in Patients With Clinical T4b Esophageal Cancer: Short-term Results.
    Sugimura K; Miyata H; Tanaka K; Makino T; Takeno A; Shiraishi O; Motoori M; Yamasaki M; Kimura Y; Hirao M; Fujitani K; Yasuda T; Mori M; Eguchi H; Yano M; Doki Y
    Ann Surg; 2021 Dec; 274(6):e465-e472. PubMed ID: 33065643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of operative outcomes of thoracoscopic esophagectomy after triplet chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for advanced esophageal squamous cell carcinoma.
    Akiyama Y; Iwaya T; Endo F; Chiba T; Takahara T; Otsuka K; Nitta H; Koeda K; Mizuno M; Kimura Y; Sasaki A
    Surg Endosc; 2018 Jan; 32(1):391-399. PubMed ID: 28664431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma.
    Sasaki K; Uchikado Y; Omoto I; Arigami T; Osako Y; Noda M; Okumura H; Maemura K; Higashi R; Yoshiura T; Natsugoe S
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):581-587. PubMed ID: 30623230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
    Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcomes and safety of radical transmediastinal esophagectomy with preoperative docetaxel, cisplatin, and 5-fluorouracil combination chemotherapy for locally advanced squamous cell carcinoma of the thoracic esophagus.
    Yamagata Y; Saito K; Hirano K; Oya M
    World J Surg Oncol; 2020 Sep; 18(1):252. PubMed ID: 32962718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategy Treatment of cT4b Esophageal Squamous Cell Carcinoma Using Docetaxel, Cisplatin, and 5-Fluorouracil.
    Nakajima M; Muroi H; Kikuchi M; Kubo T; Takise S; Ihara K; Nakagawa M; Morita S; Nakamura T; Yamaguchi S; Kojima K
    Anticancer Res; 2022 Jul; 42(7):3725-3733. PubMed ID: 35790261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer.
    Yokota T; Kato K; Hamamoto Y; Tsubosa Y; Ogawa H; Ito Y; Hara H; Ura T; Kojima T; Chin K; Hironaka S; Kii T; Kojima Y; Akutsu Y; Matsushita H; Kawakami K; Mori K; Nagai Y; Asami C; Kitagawa Y
    Br J Cancer; 2016 Nov; 115(11):1328-1334. PubMed ID: 27811857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Outcome of Patients with Locally Advanced Clinically Unresectable Esophageal Cancer Undergoing Conversion Surgery after Induction Chemotherapy with Docetaxel Plus Cisplatin and 5-Fluorouracil.
    Abe T; Higaki E; Hosoi T; Nagao T; Bando H; Kadowaki S; Muro K; Tanaka T; Tajika M; Niwa Y; Shimizu Y
    Ann Surg Oncol; 2021 Feb; 28(2):712-721. PubMed ID: 32761331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrence Pattern Comparing Preoperative Chemoradiotherapy and Preoperative Chemotherapy with Docetaxel plus 5-Fluorouracil and Cisplatin for Advanced Esophageal Cancer.
    Sugase T; Sugimura K; Kanemura T; Takeoka T; Yamamoto M; Shinno N; Hara H; Omori T; Fujii Y; Mukai Y; Mikamori M; Hasegawa S; Haraguchi N; Akita H; Nishimura J; Wada H; Matsuda C; Yasui M; Miyata H
    Oncology; 2022; 100(12):655-665. PubMed ID: 36198297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant Triplet Chemotherapy with Docetaxel, Cisplatin plus 5-Fluorouracil versus Docetaxel, Cisplatin plus S-1 for Advanced Esophageal Squamous cell Carcinoma: Propensity Score Matched Analysis.
    Kitadani J; Ojima T; Hayata K; Goda T; Takeuchi A; Tominaga S; Fukuda N; Nakai T; Yamaue H; Kawai M
    Oncology; 2024; 102(3):228-238. PubMed ID: 37708864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of initial induction chemotherapy with 5-fluorouracil, cisplatin, and docetaxel (DCF) for T4 esophageal cancer: a propensity score-matched analysis.
    Makino T; Yamasaki M; Miyazaki Y; Wada N; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y
    Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29190316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 3-Year Overall Survival Update From a Phase 2 Study of Chemoselection With DCF and Subsequent Conversion Surgery for Locally Advanced Unresectable Esophageal Cancer.
    Yokota T; Kato K; Hamamoto Y; Tsubosa Y; Ogawa H; Ito Y; Hara H; Ura T; Kojima T; Chin K; Hironaka S; Kii T; Kojima Y; Akutsu Y; Matsushita H; Kawakami K; Mori K; Makiuchi T; Nagumo R; Kitagawa Y
    Ann Surg Oncol; 2020 Feb; 27(2):460-467. PubMed ID: 31376034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of thoracoscopic esophagectomy after induction chemotherapy for locally advanced unresectable esophageal squamous cell carcinoma.
    Akiyama Y; Iwaya T; Endo F; Nikai H; Baba S; Chiba T; Kimura T; Takahara T; Otsuka K; Nitta H; Mizuno M; Kimura Y; Koeda K; Sasaki A
    Asian J Endosc Surg; 2020 Apr; 13(2):152-159. PubMed ID: 31313511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel, Cisplatin, and 5-FU Triplet Therapy as Conversion Therapy for Locoregionally Advanced Unresectable Esophageal Squamous Cell Carcinoma.
    Chan WL; Choi CW; Wong IY; Tsang TH; Lam AT; Tse RP; Chan KK; Wong C; Law BT; Cheung EE; Chan SY; Lam KO; Kwong D; Law S
    Ann Surg Oncol; 2023 Feb; 30(2):861-870. PubMed ID: 36307666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE).
    Terada M; Hara H; Daiko H; Mizusawa J; Kadota T; Hori K; Ogawa H; Ogata T; Sakanaka K; Sakamoto T; Kato K; Kitagawa Y
    Jpn J Clin Oncol; 2019 Dec; 49(11):1055-1060. PubMed ID: 31411696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy for locally advanced esophageal cancer comparing cisplatin and 5-fluorouracil versus docetaxel plus cisplatin and 5-fluorouracil: a propensity score matching analysis.
    Nishiwaki N; Noma K; Kunitomo T; Hashimoto M; Maeda N; Tanabe S; Sakurama K; Shirakawa Y; Fujiwara T
    Esophagus; 2022 Oct; 19(4):626-638. PubMed ID: 35792947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced cervical esophageal cancer.
    Okamoto H; Taniyama Y; Sakurai T; Heishi T; Teshima J; Sato C; Maruyama S; Ito K; Onodera Y; Konno-Kumagai T; Ishida H; Kamei T
    Esophagus; 2018 Oct; 15(4):281-285. PubMed ID: 29948480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.